Press Releases

Press Releases
Date Title and Summary View
03/13/2017 Two Long-Time Board Members to Step Down After Company's 2017 Annual Meeting ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) announced today the appointment of Scott Koenig, M.D., Ph.D., to its Board of Directors. Dr. Koenig is President and Chie...
03/07/2017 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ:GLYC) today announced that the first of two patient cohorts in its Phase 2 acute myeloid leukemia (AML) trial of GMI-1271 has completed enrollment. This cohort is comprised of 25 patients 60 years of age or older with newly diagnosed AML. The study is ...
03/01/2017 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ:GLYC) today announced that pre-clinical research demonstrating the potential of two of its drug candidates, GMI-1271 and GMI-1359, against multiple myeloma will be shared via an oral presentation at the American Association for Cancer Research...
03/01/2017 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today reported progress on its clinical development programs and its financial results for the fourth quarter and year ended December 31, 2016. "In 2016, GlycoMimetics made significant progress across its clinical pipeli...
02/28/2017 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at the Cowen 37th Annual Health Care Conference in Boston, on Tuesday, March 7, 2017, at 10:40 a.m. ET. To access the live webcast ...
12/05/2016 Results to be presented today in poster at 58th American Society of Hematology (ASH) Annual Meeting and Expo ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that results of its Phase 1/2 clinical trial on its lead drug candidate GMI-1271 conti...
11/10/2016 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at two healthcare investor conferences next week, as follows: STIFEL 2016 HEALTHCARE CONFERENCEWHEN: NOVEMBER 15, 2016 AT 4:30 PM E...
11/08/2016 - Data illustrate potential for synergy between drug candidate GMI-1359 and PD-L1 antagonists when used in combination to treat solid tumors ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that data showing enhanced effectiveness of an antibody a...
11/04/2016 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today reported progress on its clinical development programs and its financial results for the quarter ended September 30, 2016. "For GlycoMimetics, the third quarter was highlighted by continued achievements in our clin...
11/03/2016 Oral presentation and six posters illustrate advancement of GlycoMimetics' pipeline Poster presentation will update clinical data from on-going AML study of GMI-1271 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announ...
1
... NextLast
Add to Briefcase = add release to Briefcase